Pharma Company Bags Rs 315 Crore Order from United Nations International Children's Emergency Fund (UNICEF)
DSIJ Intelligence-1 / 03 Oct 2025/ Categories: Mindshare, Trending
The company has a market cap of over Rs 2,500 crore and the stock is up by 58.2 per cent from its 52-week low of Rs 268.10 per share.
Panacea Biotec Limited has received a Letter of Award from the United Nations International Children's Emergency Fund (UNICEF) for a Long-Term Agreement to supply the bivalent oral polio vaccine (bOPV). This significant international contract is for the supply of bOPV in 10 and 20 vial presentations and is valued at approximately $35.65 million (around Rs.315 Crore) for the period covering the second quarter of Calendar Year 2026 and all of Calendar Year 2027. The overarching Long-Term Agreement itself extends from April 1, 2026, to March 31, 2030. This disclosure was made public under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The agreement details that the supply of the bOPV by Panacea Biotec to UNICEF is subject to applicable conditions, with the execution timeline specifically focusing on the Q2 CY2026 and CY2027 delivery periods. As part of UNICEF's transparency policy, the organization will publish key details of the award on its website. This includes the supplier's name, the vaccine(s) involved, the total award value and duration, and the awarded prices per supplier for each product presentation per year. The contract is international in nature and focuses on providing bOPV to meet UNICEF's requirements based on orders received over the specified timeframes.
About the Company
Established in 1984, Panacea Biotec Ltd stands as a research-driven biotechnology company deeply involved in the research, development, manufacturing, and marketing of a diverse portfolio encompassing branded vaccines, pharmaceutical formulations, nutraceuticals, and food & nutrition products. Notably, Panacea Biotec has emerged as one of India's leading vaccine manufacturers and has garnered recognition from the United Nations (UN) Health Agencies for its significant contributions to the Global Polio Eradication Initiative (GPEI), having supplied billions of doses of WHO-prequalified polio vaccines to over 50 countries following its comprehensive range of oral polio vaccines.
The company has a market cap of over Rs 2,500 crore and the stock is up by 58.2 per cent from its 52-week low of Rs 268.10 per share.
Disclaimer: The article is for informational purposes only and not investment advice.